Premium
Vedolizumab is safe and effective in moderate‐to‐severe inflammatory bowel disease following liver transplantation
Author(s) -
Wright Andrew P.,
Fontana Robert J.,
Stidham Ryan W.
Publication year - 2017
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.24757
Subject(s) - vedolizumab , medicine , liver transplantation , wright , inflammatory bowel disease , transplantation , gastroenterology , disease , art , art history